Division of Gastroenterology, Federal University of Santa Catarina, Florianopolis, Santa Catarina, Brazil.
Liver Int. 2015 May;35(5):1516-23. doi: 10.1111/liv.12597. Epub 2014 Jun 6.
BACKGROUND & AIMS: The idea of acute-on-chronic liver failure (ACLF) has emerged to identify those subjects with organ failure and high mortality rates. However, the absence of a precise definition has limited the clinical application and research related to the ACLF concept. We sought to validate the ACLF definition and the CLIF-SOFA Score recently proposed by the EASL-CLIF Consortium in a cohort of patients admitted for acute decompensation (AD) of cirrhosis.
In this prospective cohort study, patients were followed during their hospital stay and thirty and 90-day mortality was evaluated by phone call, in case of hospital discharge. All subjects underwent laboratory evaluation at admission.
Between December 2010 and November 2013, 192 cirrhotic patients were included. At enrollment, 46 patients (24%) met the criteria for ACLF (Grades 1, 2 and 3 in 18%, 4% and 2% respectively). The 30-day mortality was 65% in ACLF group and 12% in the remaining subjects (P < 0.001). Logistic regression analysis showed that 30-day mortality was independently associated with ascites and ACLF at admission. The Kaplan-Meier survival probability at 90-day was 92% in patients without ascites or ACLF and only 22% for patients with both ascites and ACLF. The AUROC of CLIF-SOFA in predicting 30-day mortality was 0.847 ± 0.034, with sensitivity of 64%, specificity of 90% and positive likelihood ratio of 6.61 for values ≥9.
In our single-centre experience the CLIF-SOFA and the EASL-CLIF Consortium definition of ACLF proved to be strong predictors of short-term mortality in cirrhotic patients admitted for AD.
慢加急性肝衰竭(ACLF)的概念旨在识别那些出现器官衰竭和高死亡率的患者。然而,由于缺乏精确的定义,ACLF 概念的临床应用和研究受到限制。我们旨在验证 EASL-CLIF 联合会最近提出的 ACLF 定义和 CLIF-SOFA 评分在因肝硬化急性失代偿(AD)住院的患者队列中的适用性。
在这项前瞻性队列研究中,对患者进行住院期间的随访,并通过电话评估 30 天和 90 天的死亡率,若患者已出院则通过电话通知。所有患者在入院时均进行实验室评估。
2010 年 12 月至 2013 年 11 月期间,共纳入 192 例肝硬化患者。在入组时,46 例(24%)符合 ACLF 标准(分别为 1 级、2 级和 3 级,占 18%、4%和 2%)。ACLF 组的 30 天死亡率为 65%,而其余患者为 12%(P<0.001)。Logistic 回归分析显示,30 天死亡率与入院时的腹水和 ACLF 独立相关。无腹水或 ACLF 的患者在 90 天的 Kaplan-Meier 生存概率为 92%,而同时存在腹水和 ACLF 的患者仅为 22%。CLIF-SOFA 在预测 30 天死亡率方面的 AUROC 为 0.847±0.034,其灵敏度为 64%,特异性为 90%,阳性似然比为 6.61,截断值为≥9。
在我们的单中心经验中,CLIF-SOFA 和 EASL-CLIF 联合会的 ACLF 定义被证明是预测因肝硬化 AD 住院患者短期死亡率的有力指标。